- Home
- GMAB vs KEP Comparison
GMAB vs KEP Comparison
Compare GMAB & KEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- KEP
- Stock Information
- Founded
- GMAB 1999
- KEP 1961
- Country
- GMAB Denmark
- KEP South Korea
- Employees
- GMAB N/A
- KEP N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- KEP Electric Utilities: Central
- Sector
- GMAB Health Care
- KEP Utilities
- Exchange
- GMAB Nasdaq
- KEP Nasdaq
- Market Cap
- GMAB 15.4B
- KEP 17.8B
- IPO Year
- GMAB N/A
- KEP N/A
- Fundamental
- Price
- GMAB $28.61
- KEP $13.73
- Analyst Decision
- GMAB Buy
- KEP
- Analyst Count
- GMAB 6
- KEP 0
- Target Price
- GMAB $37.60
- KEP N/A
- AVG Volume (30 Days)
- GMAB 1.4M
- KEP 370.7K
- Earning Date
- GMAB 11-05-2025
- KEP 11-11-2025
- Dividend Yield
- GMAB N/A
- KEP 0.35%
- EPS Growth
- GMAB 77.72
- KEP 138.56
- EPS
- GMAB 21.62
- KEP 7.29
- Revenue
- GMAB $3,646,881,232.00
- KEP $70,790,610,836.00
- Revenue This Year
- GMAB $22.68
- KEP $4.69
- Revenue Next Year
- GMAB $15.85
- KEP $1.94
- P/E Ratio
- GMAB $1.32
- KEP $3.71
- Revenue Growth
- GMAB 32.97
- KEP 5.55
- 52 Week Low
- GMAB $17.24
- KEP $6.68
- 52 Week High
- GMAB $28.74
- KEP $15.19
- Technical
- Relative Strength Index (RSI)
- GMAB 81.36
- KEP 51.24
- Support Level
- GMAB $27.58
- KEP $13.32
- Resistance Level
- GMAB $27.61
- KEP $14.13
- Average True Range (ATR)
- GMAB 0.37
- KEP 0.18
- MACD
- GMAB 0.26
- KEP 0.02
- Stochastic Oscillator
- GMAB 97.02
- KEP 52.36
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About KEP Korea Electric Power Corporation
Korea Electric Power Corp is an electric utility company in which the government of South Korea holds a controlling stake. The firm operates in the following segments: Transmission and distribution, Electric power generation (Nuclear), Electric power generation (Non-Nuclear), Plant maintenance & engineering service, and Others. The majority of the energy produced by the company comes from its nuclear and coal-fired assets. Korea Electric Power generates revenue through the Transmission and distribution segment. Geographically, it derives maximum revenue from Domestic operations.